

Abemaciclib monarchE

PRELIMINARY SCORE

CURATIVE

Scoring of iDFS on the same basis as DFS

NON-CURATIVE

ADJUSTMENTS

Quality of life

QoL data pending

Serious and disabling adverse effects

Other adjustments

Abemaciclib monarchE

FINAL SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Adjuvant treatment of adult patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
Experimental Arm: Abemaciclib + Standard endocrine therapy (aromatase inhibitors and/or antiestrogens with or without ovarian suppression)
Control Arm: Standard endocrine therapy

